Key result
Four-factor prothrombin complex concentrates are used to manage anticoagulation-associated bleeding and restore hemostasis in patients receiving direct oral Factor Xa inhibitors.
Why the study?
Factor Xa inhibitors prevent thrombosis but can cause severe or life-threatening bleeding, necessitating strategies such as four-factor prothrombin complex concentrates to restore hemostasis.
Does four-factor prothrombin complex concentrate improve hemostasis in patients receiving direct oral activated factor X inhibitors with severe bleeding?
Does four-factor prothrombin complex concentrate improve hemostasis in patients receiving direct oral activated factor X inhibitors with severe bleeding?
Four-factor prothrombin complex concentrates are discussed as a strategy for managing severe bleeding and restoring hemostasis in patients on Factor Xa inhibitors.
Informs DOAC bleeding management strategies; leaves open comparative efficacy pending randomized trials.
Factor Xa inhibitors prevent thrombosis but are associated with severe or life-threatening bleeding. Here, the authors present data on four-factor prothrombin complex concentrates in management of anticoagulation-associated bleeding and restoring hemostasis, including recent results from the UPRATE study.
No takes yet. Share an insight, caveat, or question.
Grottke et al. (2019) studied this question. Four-factor prothrombin complex concentrates are used to manage anticoagulation-associated bleeding and restore hemostasis in patients receiving direct oral Factor Xa inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: